ACE and diabetic kidney disease: Despite the current use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, the risk of DKD progression has still not been lowered (Bash et al., 2008; Dounousi et al., 2015), pointing to huge unsatisfied demand for innovative therapies for DKD.